Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors

Nûn K. Bentounes; Nûn K. Bentounes; Sophie Melicine; Sophie Melicine; A. Martin; A. Martin; David M. Smadja; David M. Smadja; Nicolas Gendron; Nicolas Gendron

doi:10.1016/j.jdmv.2023.04.002

Back

Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors

Article 2023 en

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2024

New anticoagulants in 2024: development of factor XI and XIa inhibitors

Nûn K. Bentounes, Nûn K. Bentounes, Sophie Melicine, Sophie Melicine, A. Martin, A. Martin, David M. Smadja, David M. Smadja, Nicolas Gendron, Nicolas Gendron

Article2024

New anticoagulants in 2024: Development of factor XI and XIa inhibitors

Nûn K Bentounes, Nûn K Bentounes, Sophie Melicine, Sophie Melicine, Anne‐Céline Martin, Anne‐Céline Martin, David M. Smadja, David M. Smadja, Nicolas Gendron, Nicolas Gendron

Article2023

[A new anticoagulant strategy: the factor XI inhibitors].

Maria Cristina Vedovati, Giancarlo Agnelli

Article2025

Use of factor XI/XIa inhibitors in patients with atrial fibrillation: Current progress and future prospects

Yue Fan, Xi Chen, Yueyun Jiang, Yugang Dong, Chen Liu, Yili Chen, Professor Gregory Lip, Wengen Zhu

Article2023

A new strategy for anticoagulation: The factor XI inhibitors

Maria Cristina Vedovati, Cecilia Becattini, Giancarlo Agnelli